U.K. Approves AstraZeneca - Alexion Deal - Quick Facts

The UK Competition and Markets Authority or CMA has approved AstraZeneca Plc.'s (AZN.L,AZN) proposed acquisition of Alexion Pharmaceuticals Inc. (ALXN). The acquisition is expected to close on 21 July 2021.

AstraZeneca noted that a group focusing on rare diseases will be created. The group will be named 'Alexion, AstraZeneca Rare Disease', and will be headquartered in Boston, US.

Last week, AstraZeneca said it received clearance from the European Commission for the proposed acquisition of Alexion Pharmaceuticals. The clearance followed competition clearances in the United States, Japan and other countries globally.

The CMA said in May that it started its investigation whether AstraZeneca Plc.'s takeover of Alexion Pharmaceuticals could reduce competition for products and services in the United Kingdom or any other markets.

In December 2020, British drug major AstraZeneca agreed to buy Alexion Pharmaceuticals for $175 per share in cash and stock, valuing the Boston-based company at $39 billion.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
CVS Health is set to recruit qualified candidates to fill 25,000 clinical and retail jobs during a one-day national career event on Friday, September 24. This will enable CVS to meet the high demand for pharmacists, pharmacy technicians, nurses, and retail store associates to support flu season, COVID-19 vaccinations and testing. Twitter, Inc. (TWTR) announced Monday that it has entered into a binding agreement to settle the consolidated class action lawsuit commenced in 2016 in the United States District Court for the Northern District of California. Under the terms of the proposed settlement, Twitter will pay $809.5 million... Drug major Pfizer has again expanded the earlier two recalls of its anti-smoking Drug Chantix (Varenicline) in the form of tablets, to now include all the lots, for the potential presence of nitrosamine impurity, N-Nitroso- varenicline, at or above the FDA interim acceptable intake limit (ADI), the U.S. Food and Drug Administration or FDA said in a statement.
Follow RTT